Director Kimberly Park filed a Form 4 with the SEC on August 28, 2026, reporting the exercise and sale of stock options in Corcept Therapeutics Incorporated (NASDAQ:CORT) on August 26, 2026.

Key Highlights

  • Option exercise: Park exercised a stock option for 30,000 shares of common stock at an exercise price of $13.49 per share on August 26, 2026.
  • Shares withheld: 3,315 shares were withheld by the issuer to cover the exercise price in connection with the net exercise of the stock options.
  • Sale of shares: 26,685 shares were sold on August 26, 2026, at a weighted average price of $122.5471 per share, with actual sale prices ranging from $122.50 to $122.80 per share.
  • Resulting ownership: Following all reported transactions, Park directly owns 0 shares of common stock and retains 30,000 shares underlying a stock option expiring September 17, 2029.
  • Option status: The stock option reported in Table II, with an exercise price of $13.49 and expiration date of September 17, 2029, is described as fully exercisable.

Kimberly Park's Option Exercise and Share Sale at Corcept Therapeutics

According to the filing, Kimberly Park, a director of Corcept Therapeutics Incorporated, executed three transactions in the company's common stock on August 26, 2026. First, Park exercised a stock option covering 30,000 shares of common stock at a price of $13.49 per share, recorded as transaction code "M" (exercise of in-the-money or at-the-money derivative security). The option, which the filing describes as fully exercisable, carries an expiration date of September 17, 2029.

Following the exercise, the filing reports that 3,315 shares were withheld by the issuer under transaction code "F" at a price of $122.09 per share. The filing explains that "these shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein." The remaining 26,685 shares were then sold on the same date under transaction code "S" at a weighted average price of $122.5471 per share. The filing notes that actual sale prices ranged from $122.50 to $122.80 per share, and states that information on the exact number of shares sold at each price can be obtained from the issuer upon request.

After all three transactions, the filing reports Park's direct beneficial ownership of common stock stands at 0 shares. The filing was signed by Joseph Douglas Lyon as attorney-in-fact for Kimberly Park on August 28, 2026, with a note that the power of attorney under which the form was signed is on file with the Commission.

What Was Disclosed

The filing discloses the net exercise of a stock option for 30,000 shares, the withholding of 3,315 shares to cover the exercise price, and the subsequent sale of 26,685 shares by Corcept Therapeutics director Kimberly Park on August 26, 2026.